Key factors
sym | ARPO |
exch | US |
MCap | 104.85M |
Beta | 1.646 |
EPS | -0.40 |
Div date | 0000-00-00 |
Yesterday
sym | ARPO |
exch | US |
close | 26.0 |
50 Day MA | 31.63 |
200 Day MA | 25.84 |
Target Price | 22.0 |
Market Cap Mln | 104.85 |
Share statistics
Shares Outstanding | 47.66M |
Shares Float | 25.87M |
Percent Institutions | 71.05 |
PercentInsiders | 4.274 |
SharesShort | 2750.51K |
Short Ratio | 1.81 |
Shares Short Prior Month | 3525.79K |
Short Percent | 10.62 |
Income
Gross Profit TTM | 15.0M |
EBITDA | -11.5M |
Diluted Eps TTM | -0.40 |
earning
Earnings Share | -0.40 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 0000-00-00 |
business
Enterprise Value Ebitda | 0.242 |
Enterprise Value Revenue | 4.011 |
Book Value /share | 0.742 |
Price Book MRQ | 2.977 |
Price Sales TTM | 6.142 |
ReturnOnAssetsTTM | -0.31 |
ReturnOnEquityTTM | -0.47 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US00810B1052 |
CIK | 1422142 |
Code | ARPO |
CUSIP | 00810B105 |
Employer Id Number | 61-1547850 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2021-10-31 |
is Delisted | 1 |
Delisted Date | 2021-09-03 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 12.0 |
IPODate | 2017-08-08 |
International Domestic | Domestic |
MostRecent Quarter | 2021-06-30 |
Contact
Name | Aerpio Pharmaceuticals Inc |
Address | 9987 Carver Road, Cincinnati, OH, United States, 45242 |
Country Name | USA |
Phone | 513 985 1920 |
Web URL | www.aerpio.com |
Logo URL | /img/logos/US/ARPO.png |
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.